文献速递心力衰竭与心肌病

沙库巴曲缬沙坦在射血分数保留心衰合并衰弱患者中的疗效

Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2022-08-29

基于PARAGON-HF试验中4796例射血分数保留心衰患者,采用Rockwood累积缺陷法评估衰弱。衰弱越重主要终点风险越高,沙库巴曲缬沙坦较缬沙坦在衰弱程度增加时显示更大幅度终点减少,但按衰弱指数分类变量分析时交互作用不显著。

要点

  • 衰弱在HFpEF中普遍:45.2%为1类(不衰弱)、43.5%为2类(较衰弱)、11.4%为3类(最衰弱)。
  • 衰弱越重主要终点风险越高:2类率比2.19(95%CI 1.85-2.60),3类率比3.29(95%CI 2.65-4.09)。
  • 沙库巴曲缬沙坦较缬沙坦的获益随衰弱加重而增大,但分类变量交互作用不显著(Pinteraction=0.23)。

核心结论

  • 在HFpEF患者中衰弱常见且与更差结局相关。
  • 沙库巴曲缬沙坦较缬沙坦在衰弱程度增加时似乎显示更大幅度主要终点减少,但衰弱指数作为分类变量时交互作用不显著。

研究设计与样本

  • PARAGON-HF试验(NCT01920711)随机化4796例射血分数保留心衰患者。
  • 采用Rockwood累积缺陷法测量衰弱,衰弱指数在4795例中可计算。
  • 主要终点为总心衰住院或心血管死亡。

主要发现

  • 衰弱指数分类:1类(FI≤0.210,不衰弱)45.2%;2类(FI 0.211-0.310,较衰弱)43.5%;3类(FI≥0.311,最衰弱)11.4%。
  • 衰弱指数分类与主要终点呈分级关系:2类率比2.19(95%CI 1.85-2.60),3类率比3.29(95%CI 2.65-4.09),1类为参照。
  • 沙库巴曲缬沙坦vs缬沙坦主要终点率比从最低到最高衰弱指数分类分别为0.98(95%CI 0.76-1.27)、0.92(95%CI 0.76-1.12)、0.69(95%CI 0.51-0.95),Pinteraction=0.23。
  • 衰弱指数作为连续变量时,与治疗交互作用对主要结局显著(Pinteraction=0.002),对总心衰住院显著(Pinteraction<0.001),最衰弱者获益更大。

临床怎么用

  • 对HFpEF患者应评估衰弱状态,衰弱越重结局风险越高。
  • 衰弱程度较高的HFpEF患者使用沙库巴曲缬沙坦可能获益更大,但分类变量分析交互作用不显著,需结合连续评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is an increasingly common problem, and frail patients are less likely to receive new pharmacologic therapies because the risk-benefit profile is perceived to be less favorable than in nonfrail patients. OBJECTIVES: This study investigated the efficacy of sacubitril/valsartan according to frailty status in 4,796 patients with heart failure with preserved ejection fraction randomized in the PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction) trial. METHODS: Frailty was measured by using the Rockwood cumulative deficit approach. The primary endpoint was total heart failure hospitalizations or cardiovascular death. RESULTS: A frailty index (FI) was calculable in 4,795 patients. In total, 45.2% had class 1 frailty (FI ≤0.210, not frail), 43.5% had class 2 frailty (FI 0.211-0.310, more frail), and 11.4% had class 3 frailty (FI ≥0.311, most frail). There was a graded relationship between FI class and the primary endpoint, with a significantly higher risk associated with greater frailty (class 1: reference; class 2 rate ratio: 2.19 [95% CI: 1.85-2.60]; class 3 rate ratio: 3.29 [95% CI: 2.65-4.09]). The effect of sacubitril/valsartan vs valsartan on the primary endpoint from lowest to highest FI class (as a rate ratio) was: 0.98 [95% CI: 0.76-1.27], 0.92 [95% CI: 0.76-1.12], and 0.69 [95% CI: 0.51-0.95]), respectively (Pinteraction = 0.23). When FI was examined as a continuous variable, the interaction with treatment was significant for the primary outcome (Pinteraction = 0.002) and total heart failure hospitalizations (Pinteraction < 0.001), with those most frail deriving greater benefit. CONCLUSIONS: Frailty was common in heart failure with preserved ejection fraction and associated with worse outcomes. Compared with valsartan, sacubitril/valsartan seemed to show a greater reduction in the primary endpoint with increasing frailty, although this was not significant when FI was examined as a categorical variable. (Prospective Comparison of ARNI With ARB Global Outcomes in Heart Failure With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Butt, Dewan, Jhund, et al. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 36050227. doi:10.1016/j.jacc.2022.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。